) will now enjoy an additional six months of exclusivity in the US
for one of its lead products, Cymbalta. The US Food and Drug
Administration (FDA) recently granted pediatric exclusivity to
Cymbalta, which means that Cymbalta will be protected from generic
competition in the US until December 2013 instead of June 2013.
Eli Lilly, however, pointed out that Cymbalta is not approved
for use in children and the company does not intend to seek
approval for this patient population.
Cymbalta, one of the key products in Eli Lilly's pipeline, is
approved for a wide range of indications including the treatment of
major depressive disorder and generalized anxiety disorder and the
management of diabetic peripheral neuropathic pain and
fibromyalgia. Cymbalta is also approved for the management of
chronic musculoskeletal pain in people with chronic osteoarthritis
pain or chronic low back pain.
Cymbalta, which accounted for 17.1% of Eli Lilly's total
revenues in 2011, posted total sales of $4.16 billion in 2011. US
sales were $3.2 billion in 2011.
Cymbalta continues to perform well with first quarter 2012 sales
in the US coming in at $857.6 million. Given Cymbalta's current
performance, the additional six month exclusivity period could
result in sales of at least $1.6 billion in the US.
This bodes well for Eli Lilly, which currently faces a major
patent cliff. Zyprexa, which posted sales of $4.62 billion in 2011,
lost exclusivity in the EU and US in late 2011. Companies like
) have launched their generic version of the product and we expect
a rapid erosion in Zyprexa sales. In fact, Eli Lilly expects
Zyprexa sales to fall by more than $3 billion in 2012. First
quarter 2012 Zyprexa sales fell 56% to $562.7 million.
We currently have a Neutral recommendation on Eli Lilly, which
carries a Zacks #3 Rank (short-term Hold rating).
LILLY ELI & CO (LLY): Free Stock Analysis
DOCTOR REDDYS (RDY): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.